Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
The biotech is laying off 55% of its employees and cutting back internal R&D work to focus on lead program emiltatug ledadotin.
Nick Paul Taylor
May 6, 2025 9:40am
Elevation faces activist investor demands to wind down
Apr 17, 2025 10:00am
BioNTech backing powers DualityBio toward $200M Hong Kong IPO
Apr 7, 2025 8:21am
Boehringer commits $31M to ADC R&D via NBE Therapeutics facility
Apr 3, 2025 5:30am
AbbVie alleges Genmab 'willfully blind' to trade secret theft
Mar 24, 2025 5:51am
Eisai's abandoned Enhertu challenger set to live on at BlissBio
Mar 21, 2025 7:20am
